Form D · Biotechnology
Cadence Neuroscience, Inc.
Sammamish, WA · CIK 0001712390
Offering snapshot reported Feb 28, 2023 · SEC filing
- Reported sold
- $26M Offering amount: $26M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 21, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 28, 2023 | Initial | $26,029,994 | No comparison | 7 | SEC filing |
| Sep 23, 2019 | Initial | $2,999,999 | No comparison | 1 | SEC filing |
| Jul 31, 2017 | Initial | $0 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-474511
Source: Form D, filed Feb 28, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gerry Brunk | Director |
| Kevin Chu | Director |
| Andrew Firlik | Director |
| John Harris | Director |
| Kent Leyde | Director, Executive |
| Warren Douglas Sheffield | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2036 223 Rd Place Ne
Sammamish, WA, 98074
Sammamish, WA, 98074